Literature DB >> 19318491

Association of MDM2 SNP309, age of onset, and gender in cutaneous melanoma.

Elnaz F Firoz1, Melanie Warycha, Jan Zakrzewski, Danuta Pollens, Guimin Wang, Richard Shapiro, Russell Berman, Anna Pavlick, Prashiela Manga, Harry Ostrer, Julide Tok Celebi, Hideko Kamino, Farbod Darvishian, Linda Rolnitzky, Judith D Goldberg, Iman Osman, David Polsky.   

Abstract

PURPOSE: In certain cancers, MDM2 SNP309 has been associated with early tumor onset in women. In melanoma, incidence rates are higher in women than in men among individuals less than 40 years of age, but among those older than 50 years of age, melanoma is more frequent in men than in women. To investigate this difference, we examined the association among MDM2 SNP309, age at diagnosis, and gender among melanoma patients. EXPERIMENTAL
DESIGN: Prospectively enrolled melanoma patients (N = 227) were evaluated for MDM2 SNP309 and the related polymorphism, p53 Arg72Pro. DNA was isolated from patient blood samples, and genotypes were analyzed by PCR-restriction fragment length polymorphism. Associations among MDM2 SNP309, p53 Arg72Pro, age at diagnosis, and clinicopathologic features of melanoma were analyzed.
RESULTS: The median age at diagnosis was 13 years earlier among women with a SNP309 GG genotype (46 years) compared with women with TG+TT genotypes (59 years; P = 0.19). Analyses using age dichotomized at each decade indicated that women with a GG genotype had significantly higher risks of being diagnosed with melanoma at ages <50 years compared with women >or=50 years, but not when the comparison was made between women <60 and >or=60 years. At ages <50 years, women with a GG genotype had a 3.89 times greater chance of being diagnosed compared with women with TG+TT genotypes (P = 0.01). Similar observations were not seen among men.
CONCLUSIONS: Our data suggest that MDM2 may play an important role in the development of melanoma in women. The MDM2 SNP309 genotype may help identify women at risk of developing melanoma at a young age.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19318491      PMCID: PMC3881546          DOI: 10.1158/1078-0432.CCR-08-2678

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  63 in total

1.  HDM2 protein overexpression and prognosis in primary malignant melanoma.

Authors:  David Polsky; Kate Melzer; Carole Hazan; Katherine S Panageas; Klaus Busam; Maria Drobnjak; Hideko Kamino; Joanna G Spira; Alfred W Kopf; Alan Houghton; Carlos Cordon-Cardo; Iman Osman
Journal:  J Natl Cancer Inst       Date:  2002-12-04       Impact factor: 13.506

2.  p53 codon 72 Arg homozygotes are associated with an increased risk of cutaneous melanoma.

Authors:  Hongbing Shen; Zhensheng Liu; Sara S Strom; Margaret R Spitz; Jeffrey E Lee; Jeffrey E Gershenwald; Merrick I Ross; Paul F Mansfield; Madeleine Duvic; Honnavara N Ananthaswamy; Qingyi Wei
Journal:  J Invest Dermatol       Date:  2003-12       Impact factor: 8.551

3.  MDM2/p53 protein expression in the development of colorectal adenocarcinoma.

Authors:  G Abdel-Fattah; B Yoffe; B Krishnan; V Khaoustov; K Itani
Journal:  J Gastrointest Surg       Date:  2000 Jan-Feb       Impact factor: 3.452

4.  Ligand-, cell-, and estrogen receptor subtype (alpha/beta)-dependent activation at GC-rich (Sp1) promoter elements.

Authors:  B Saville; M Wormke; F Wang; T Nguyen; E Enmark; G Kuiper; J A Gustafsson; S Safe
Journal:  J Biol Chem       Date:  2000-02-25       Impact factor: 5.157

5.  Increased expression of estrogen receptor beta mRNA in tamoxifen-resistant breast cancer patients.

Authors:  V Speirs; C Malone; D S Walton; M J Kerin; S L Atkin
Journal:  Cancer Res       Date:  1999-11-01       Impact factor: 12.701

6.  Clinical significance of apoptosis-related factors p53, Mdm2, and Bcl-2 in advanced ovarian cancer.

Authors:  M Baekelandt; G B Kristensen; J M Nesland; C G Tropé; R Holm
Journal:  J Clin Oncol       Date:  1999-07       Impact factor: 44.544

7.  Estrogen receptor beta (ER beta) level but not its ER beta cx variant helps to predict tamoxifen resistance in breast cancer.

Authors:  Majida Esslimani-Sahla; Joelle Simony-Lafontaine; Andrew Kramar; Roselyne Lavaill; Caroline Mollevi; Margaret Warner; Jan-Ake Gustafsson; Henri Rochefort
Journal:  Clin Cancer Res       Date:  2004-09-01       Impact factor: 12.531

Review 8.  Use of tamoxifen in the treatment of malignant melanoma.

Authors:  Marko B Lens; Tony Reiman; Amna F Husain
Journal:  Cancer       Date:  2003-10-01       Impact factor: 6.860

9.  MDM2 SNP309 accelerates breast and ovarian carcinogenesis in BRCA1 and BRCA2 carriers of Jewish-Ashkenazi descent.

Authors:  Ronit I Yarden; Eitan Friedman; Sally Metsuyanim; Tsviya Olender; Edna Ben-Asher; Moshe Zvi Papa
Journal:  Breast Cancer Res Treat       Date:  2007-11-18       Impact factor: 4.872

10.  The expression of murine double minute 2 is a favorable prognostic marker in esophageal squamous cell carcinoma without p53 protein accumulation.

Authors:  Hiroaki Saito; Shunichi Tsujitani; Shinichi Oka; Masahide Ikeguchi; Michio Maeta; Nobuaki Kaibara
Journal:  Ann Surg Oncol       Date:  2002-06       Impact factor: 5.344

View more
  20 in total

Review 1.  Single-nucleotide polymorphisms in the p53 signaling pathway.

Authors:  Lukasz F Grochola; Jorge Zeron-Medina; Sophie Mériaux; Gareth L Bond
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-12-09       Impact factor: 10.005

2.  Melanoma in adolescents and young adults (ages 15-39 years): United States, 1999-2006.

Authors:  Hannah K Weir; Loraine D Marrett; Vilma Cokkinides; Jill Barnholtz-Sloan; Pragna Patel; Eric Tai; Ahmedin Jemal; Jun Li; Julian Kim; Donatus U Ekwueme
Journal:  J Am Acad Dermatol       Date:  2011-11       Impact factor: 11.527

3.  The power of protein interaction networks for associating genes with diseases.

Authors:  Saket Navlakha; Carl Kingsford
Journal:  Bioinformatics       Date:  2010-02-24       Impact factor: 6.937

4.  MDM2 gene polymorphisms and risk of classic Kaposi's sarcoma among Iranian patients.

Authors:  Sajad Varmazyar; Sayed Mahdi Marashi; Zabihollah Shoja; Maria Lina Tornesello; Franco M Buonaguro; Shohreh Shahmahmoodi; Zahra Safaie-Naraghi; Somayeh Jalilvand
Journal:  Med Microbiol Immunol       Date:  2017-01-12       Impact factor: 3.402

5.  B7-H1-dependent sex-related differences in tumor immunity and immunotherapy responses.

Authors:  Pei-Yi Lin; Lishi Sun; Suzanne R Thibodeaux; Sara M Ludwig; Ratna K Vadlamudi; Vincent J Hurez; Rumana Bahar; Mark J Kious; Carolina B Livi; Shawna R Wall; Lieping Chen; Bin Zhang; Tahiro Shin; Tyler J Curiel
Journal:  J Immunol       Date:  2010-08-04       Impact factor: 5.422

6.  Effects of MDM2 promoter polymorphisms and p53 codon 72 polymorphism on risk and age at onset of squamous cell carcinoma of the head and neck.

Authors:  Hongping Yu; Yu-jing Huang; Zhensheng Liu; Li-E Wang; Guojun Li; Erich M Sturgis; David G Johnson; Qingyi Wei
Journal:  Mol Carcinog       Date:  2011-06-07       Impact factor: 4.784

7.  Impact of the Mdm2(SNP309-G) allele on a murine model of colorectal cancer.

Authors:  X Zhang; L Pageon; S M Post
Journal:  Oncogene       Date:  2014-12-01       Impact factor: 9.867

8.  Germline mutations and polymorphisms in the origins of cancers in women.

Authors:  Kim M Hirshfield; Timothy R Rebbeck; Arnold J Levine
Journal:  J Oncol       Date:  2010-01-10       Impact factor: 4.375

9.  Altered tumor formation and evolutionary selection of genetic variants in the human MDM4 oncogene.

Authors:  Gurinder Singh Atwal; Tomas Kirchhoff; Elisabeth E Bond; Marco Montagna; Marco Monagna; Chiara Menin; Roberta Bertorelle; Maria Chiara Scaini; Frank Bartel; Anja Böhnke; Christina Pempe; Elise Gradhand; Steffen Hauptmann; Kenneth Offit; Arnold J Levine; Gareth L Bond
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-04       Impact factor: 11.205

10.  Zebrafish have a competent p53-dependent nucleotide excision repair pathway to resolve ultraviolet B-induced DNA damage in the skin.

Authors:  Zhiqiang Zeng; Jennifer Richardson; Daniel Verduzco; David L Mitchell; E Elizabeth Patton
Journal:  Zebrafish       Date:  2009-12       Impact factor: 1.985

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.